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Dear Editor,
Having previously published on the usage of white blood cells
(WBC) in diagnostics of X-chromosome linked Danon disease (DD,
LAMP2 deﬁciency), we would like to respond to claims made by
Hashida and colleagues in their report ‘‘Early diagnosis of Danon
disease: Flow cytometric detection of lysosome-associated mem-
brane protein-2-negative leukocytes’’ [1]. Our aim is to rectify
the statements on novelty of the LAMP2 ﬂow cytometric (FC) assay
and its utility in early diagnosis and/or screening for DD patients.
We would further like to comment on the genetic setup in the
presented DD family and clarify the interpretation of WBC
LAMP2 expression patterns in female patients as outlined by the
authors.
LAMP2 western blotting in WBCs was previously suggested as a
screening tool in DD [2]. Regelsberger et al. [3] presented a LAMP1/
LAMP2 immunohistochemical (IHC) assay in isolated peripheral
blood mononuclear cells and also LAMP1/LAMP2 detection by FC.
Building upon all these results, we showed the utility of LAMP2 IHC
directly in peripheral blood smears and provided (in a cohort of
healthy donors) polychromatic FC reference data for LAMP1/LAMP2
expression in a range of WBC lineages (B lymphocytes, CD8+
and CD4+ T lymphocytes, natural killer cells, monocytes, and
granulocytes) [4]. Using FC, we demonstrated impacts of
X-chromosome inactivation (XCI) on LAMP2 expression proﬁles in
WBCs of heterozygous female DD patient(s)/carrier(s) and exten-
sively debated merits of the assay speciﬁcally for this DD patient
group.
In May 2013, we published a study [5] in two male DD patients
and their clinically unaffected mother all carrying a duplication of
LAMP2 exons 4 and 5. To detect the extremely rare LAMP2 deﬁcient
WBC populations (0.06% of granulocytes and 0.13% of monocytes),
and thus establish the mother’s genetic setup as a somatic/
germinal mosaic, we adapted our FC assay to conditions utilized to
detect minimal (hemato-oncological) residual disease. Consecu-
tive to these analyses, we excluded (to the limits of the molecular
genetic method used) the theoretical possibility of the mother
being a chimera.
The methodological setup, including gating strategies and
comparison of sensitivity of the two FC protocols (conventional [4]
vs. rare deﬁcient cell detection) were presented [5].
In light of the published data [2–5], we disagree with the
statements by Hashida et al. regarding the novelty of the FC
LAMP1/LAMP2 assay as well as its usage to identify female DD0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightspatients/carriers. Similarly, the utility of WBCs and/or FC in DD
screening has been directly implied [2–5]. Although brieﬂy
referenced in the Introduction, the works by Regelsberger et al.
[3] and us [4], despite of direct relevance, remain uncited in the
rest of the manuscript. Our work [5], which clearly demon-
strates the practical sensitivity limits of the LAMP2 FC assay (by
an order greater than those presented by Hashida et al.), was
neglected.
Hashida et al. describe ‘‘. . .a family with DD that has no
apparent inheritance’’. Similar to reports by us [5] and others
(referenced in [5]), the presented female II.4, who mothered one
male (symptomatic proband) and two female (monozygotic twins)
DD patients all carrying an identical LAMP2 mutation, may have
suffered from germinal or somatic/germinal mosaicism. The
inability to identify the mutation in her WBCs could have been
a result of its restricted tissue distribution and/or sensitivity limits
of the detection method used. Interestingly, LAMP2 FC as reported
previously [5] might have potentially demonstrated the minimal
amounts of LAMP2 deﬁcient cells.
We also consider the use of the term chimerism by Hashida
et al. in relation to the interpretation of both the WBC LAMP2
expression proﬁles identiﬁed in III.5 or III.6 (Fig. 4) and of the
general results of the FC assay (Discussion) problematic. The
protocols as described in the Methods, do not, in our opinion, allow
conclusion of presence of cellular populations with disparate
genomic contents originating from different zygotes [6] in either of
the two females.
While we appreciate promotion of LAMP2 FC in DD screening
and diagnostics, the manuscript by Hashida et al. is, in our opinion,
methodologically replicative and neglects relevant data previously
published by other authors. It also provides an ambiguous
interpretation of the genetic relations in the presented family
and introduces confusion by substitution/improper usage of the
term chimerism for the likely observed phenomenon of mosaic
expression due to XCI.
Given the above stated, we feel that a commentary/correction
by the authors clearly highlighting the novel aspects both in the
presented FC methodology and in the interpretation of the LAMP2
expression proﬁles of heterozygous female DD patients/carriers is
justiﬁed. We would further appreciate a clariﬁcation of the genetic
setup in the family and rectiﬁcation of usage of the term chimerism
so that the readership of the Journal of Cardiology is provided with
unambiguous information in these complex matters.
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Author’s reply
Danon disease is an X-linked myopathy that was ﬁrst reported
by Danon et al. in 1981 as a ‘‘ Lysosomal glycogen storage disease
with normal acid maltase’’ [1]. The disease is characterized by
three major symptoms, cardiomyopathy, muscle weakness,
and mild mental retardation, and has a wide spectrum of
clinical features. Although male patients usually develop severesymptoms, female patients tend to be severely affected in case of
cardiomyopathy. Moreover, the frequency of Danon disease
has recently been suggested to be higher than originally
considered. Therefore, a method is needed that can easily diagnose
Danon disease before onset, regardless of the family history or
gender.
In 2008, we experienced a case of a 13-year-old boy with Danon
disease. During the diagnosis of this case, the validity of a ﬂow
cytometry method was conﬁrmed, and the subsequent screening
of the proband’s family demonstrated that the method was
applicable for diagnosing a presymptomatic case of Danon disease
in a female patient. This is the ﬁrst report that demonstrated the
validity of a ﬂow cytometry method for intra-family search of
Danon disease within the affected family and successful screening
of a presymptomatic case [2]. This result indicates that the
method is a useful screening technique for searching the cause of
cardiomyopathy of unknown etiology. However, a critical refer-
ence was not cited in this study report [3]. This was simply caused
by an overlook that occurred between the diagnosis of the
proband (2008) and the ﬁnal acceptance of the manuscript by
the Journal of Cardiology; that is, after completion of the project, the
manuscript went through several review processes by multiple
journals and the error occurred during this process. We sincerely
apologize for our carelessness.
The purpose of this article is not to discuss the genetic
background of a case in which genetic abnormalities were not
identiﬁed by a standard genetic test in the mother of the child with
the X-linked Danon disease or a case where identiﬁcation was
challenging even with our ﬂow cytometry method. In addition, it
remains unknown whether females with mosaicism consistently
show the phenotype of Danon disease. As suggested, a detailed
examination of the genotype of the mother is essential to elucidate
the pathology; however, this is beyond the scope of this project.
Nevertheless, it does not change the fact that this method is useful
for diagnosing myopathy that has already developed or for
diagnosing a presymptomatic heterozygous female with Danon
disease who has a deﬁnite chance of developing the symptom in
the future. This is the ﬁrst study that demonstrated the validity
of this method.
Although the mother was described to have ‘‘chimerism’’,
‘‘mosaicism’’ is the correct term as suggested and we have revised
it accordingly.
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